Whitepaper: Six Changes that Pharmaceutical Companies Should Consider in Response to COVID-19

[Fill out the form below to access the whitepaper]

In the wake of the global pandemic of COVID-19, also known and SARS-COV-2, regulators, health authorities, and lawmakers across the globe have rushed to implement countermeasures and develop best practices to curtail the spread.

They have also taken note of how the spread of the disease, and the mitigation efforts put in place, will impact clinical trials across the globe.  To this end, several regulatory agencies have issued guidance documents to assist sponsors in making decisions for managing clinical studies at all stages.

Experts at MMS have reviewed these guidance documents and taken into account the current state of clinical research globally to ensure our services align with these new challenges, whether those sponsors be virtual or large firms with treatments for common illnesses or rare conditions. What has been identified are key areas of change faced by the industry.

Assessing risk in the current environment

Adjusting to the COVID-19 pandemic is proving to be difficult and is likely to take every sponsor longer than they would like, especially as…

Download the whitepaper

Suggested For You

perspectives

November 6th, 2024

How to Successfully Manage Rescue Studies and Turn Around Clinical Trials Facing Failure

perspectives

October 29th, 2024

Why Outsourcing QC of Regulatory and Medical Writing Documents is a Competitive Advantage for Large Pharma Companies

perspectives

October 22nd, 2024

Choosing the Right Clinical Trial Design: A Crucial Step in Protocol Development

perspectives

October 15th, 2024

Putting the Action in Diversity Action Plans and the Real-Time Data Visualization Technology Needed to Ensure It Happens

perspectives

October 8th, 2024

Diversity Action Plan Guidance Part I: Implications for Sponsors

perspectives

September 30th, 2024

Meet the Leaders Driving MMS’s European Growth

perspectives

September 30th, 2024

The Future of Data Management and Biostatistics: Trends and Technologies Shaping the Industry

perspectives

September 24th, 2024

Embracing Quality Management Maturity (QMM) at the Cornerstone of the Pharmaceutical Industry

perspectives

September 11th, 2024

From Historical Precedent to Modern Approvals: Lessons Learned on OTC Drug Products for FDA OMORs

perspectives

September 4th, 2024

Email Security – Navigating Through the Process of Validation and Compliance with Healthcare Business Stakeholders

perspectives

August 27th, 2024

Optimizing Oncology Drug Development: FDA Expedited Pathways, Real-Time Review, and Global Programs

perspectives

August 20th, 2024

Clinical Study Protocols: A Comprehensive Guide to Best Practices From A Senior Medical Writer